Pharmaceutical contribution rarely gets the visibility it deserves outside specialist circles. The Association of the British Pharmaceutical Industry's updated Pharmaceutical Impact Map, launched on 14 July 2026, addresses that directly for the UK, bringing together data on 125,702 jobs in pharmaceutical manufacturing or research, a £20.4 billion gross value added contribution, 3,658 NHS-industry collaborations, and 186 manufacturing sites across England, Scotland, Wales, and Northern Ireland. It is a compelling demonstration of what a mature life sciences ecosystem looks like when its contribution is mapped, communicated, and placed in front of policymakers, investors, and the communities the industry serves. For life sciences Ireland, the map is not just a UK story. It is a benchmark and a prompt.

Ireland's own pharmaceutical sector data, published in the Goodbody Economic Report for IPHA in March 2026, tells an equally remarkable story, and in several dimensions a more concentrated one. Pharma exports reached €139 billion in 2025, representing 53% of all Irish goods exports and 41% of GNI*, with 75,000 workers employed directly and indirectly in pharma and related activities, and the sector paying an estimated €6 billion in total taxes in 2023. Ireland is the EU's second largest pharmaceutical exporter and hosts more FDA-registered drug manufacturing sites per capita than any other European country. The ABPI's 125,702 UK jobs figure is substantial. Ireland's 75,000, in a country of 5.5 million people, is proportionally extraordinary.

The pharmaceutical manufacturing and research and development depth underpinning those numbers is not accidental. Ireland's biopharma industry is forecast to add 21,000 jobs by 2027, with record-breaking investment in 2024 seeing the sector raise €491.3 million across 89 venture capital deals, fuelling biotechnology start-ups, pharmaceutical innovation, and capacity expansion. IDA Ireland's Adapt Intelligently strategy for 2025 to 2029 identifies life sciences as one of six key strategic sectors, with biopharmaceutical manufacturing, drug development, and advanced therapeutics at the centre of its foreign direct investment targets. Institutions including NIBRT, the National Institute for Bioprocessing Research and Training, provide the specialised training pipeline that keeps Ireland's regulatory affairs and quality assurance standards among the highest in the world.

Three actions would allow Ireland to use this moment of ABPI-inspired visibility to its own advantage. First, the Irish Pharmaceutical Healthcare Association should develop an equivalent interactive impact map for Ireland, enabling pharmaceutical companies, community organisations, and policymakers to visualise the sector's contribution at county level rather than relying on national aggregate figures that understate local economic depth. Second, medicines access and pharmaceutical leadership organisations should use Ireland's EU Presidency term, which runs until December 2026, to showcase Ireland's biologics and advanced therapeutics manufacturing credentials as a model for European supply chain resilience, connecting economic contribution data to the Critical Medicines Act's strategic autonomy objectives. Third, Enterprise Ireland and IDA Ireland should jointly develop a life sciences Ireland employer communications framework that translates sector-wide data into the community-level narratives the ABPI map demonstrates are most effective at building public understanding and political support for continued investment.

The ABPI map is a reminder that data alone does not build the case for a sector. Visibility, communication, and the consistent linking of pharmaceutical contribution to patient outcomes, jobs, and community investment are what convert economic statistics into durable political and public support. Ireland has the data. The task is making it as visible as the sector deserves.

(The views expressed by the writer are his/her own and do not necessarily reflect the views or positions of BusinessRiver.)